370 related articles for article (PubMed ID: 29343642)
1. Mechanogenetics for the remote and noninvasive control of cancer immunotherapy.
Pan Y; Yoon S; Sun J; Huang Z; Lee C; Allen M; Wu Y; Chang YJ; Sadelain M; Shung KK; Chien S; Wang Y
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):992-997. PubMed ID: 29343642
[TBL] [Abstract][Full Text] [Related]
2. Mechanogenetics for cellular engineering and cancer immunotherapy.
Zhu L; Wu Y; Yoon CW; Wang Y
Curr Opin Biotechnol; 2020 Dec; 66():88-94. PubMed ID: 32717634
[TBL] [Abstract][Full Text] [Related]
3. Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.
Chakravarti D; Caraballo LD; Weinberg BH; Wong WW
ACS Synth Biol; 2019 Aug; 8(8):1744-1754. PubMed ID: 31268301
[TBL] [Abstract][Full Text] [Related]
4. Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation.
Liu CSC; Raychaudhuri D; Paul B; Chakrabarty Y; Ghosh AR; Rahaman O; Talukdar A; Ganguly D
J Immunol; 2018 Feb; 200(4):1255-1260. PubMed ID: 29330322
[TBL] [Abstract][Full Text] [Related]
5. A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells.
Jaalouk DE; Lejeune L; Couture C; Galipeau J
Virol J; 2006 Nov; 3():97. PubMed ID: 17118192
[TBL] [Abstract][Full Text] [Related]
6. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
7. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
9. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
11. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
Ramachandran M; Dimberg A; Essand M
Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
[TBL] [Abstract][Full Text] [Related]
12. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
Kenderian SS; Ruella M; Gill S; Kalos M
Cancer Res; 2014 Nov; 74(22):6383-9. PubMed ID: 25371415
[TBL] [Abstract][Full Text] [Related]
14. Activation of Piezo1 mechanosensitive ion channel in HEK293T cells by 30 MHz vertically deployed surface acoustic waves.
Liao D; Li F; Lu D; Zhong P
Biochem Biophys Res Commun; 2019 Oct; 518(3):541-547. PubMed ID: 31451220
[TBL] [Abstract][Full Text] [Related]
15. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.
Themeli M; Sadelain M
Trends Mol Med; 2016 Apr; 22(4):271-273. PubMed ID: 26971630
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptors: driving immunology towards synthetic biology.
Sadelain M
Curr Opin Immunol; 2016 Aug; 41():68-76. PubMed ID: 27372731
[TBL] [Abstract][Full Text] [Related]
18. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
19. T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer.
Eisenberg V; Hoogi S; Shamul A; Barliya T; Cohen CJ
Adv Drug Deliv Rev; 2019 Feb; 141():23-40. PubMed ID: 30653988
[TBL] [Abstract][Full Text] [Related]
20. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
